Company intelligence / Profile preview

prototype

San Francisco, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Prototype is an early-stage biotechnology company focused on developing next-generation targeted protein degradation (TPD) therapies. The company leverages a proprietary platform to design small molecules, including molecular glues and bifunctional degraders, aimed at previously undruggable targets in oncology and other serious diseases. By optimizing the recruitment of E3 ligases, Prototype seeks to expand the reach of protein degradation beyond current industry standards. The company is currently in the pre-clinical stage, building a pipeline of candidates for hematologic and solid tumor indications.

Therapeutic areas: Oncology
Modalities: Small moleculeMolecular glue therapyProteolysis-targeting chimera therapy
Industry: Biotech

Beyond the preview

Go deeper on prototype.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on prototype.

Explore the full profile